Dr. Falk Pharma
funded university research (Tampere University, University of Oulu) on ZED1227, an oral TG2 inhibitor that in a 2024 study protected patients consuming 3 grams of daily gluten for six weeks from measurable intestinal mucosal damage and inflammation at a 100 mg daily dose,…
- Country
- Germany
Coverage
| CN | EU | US | |
|---|---|---|---|
| food-alt-protein | ✓ | ✓ | ✓ |
Regulatorsemafda
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| Enzymatic therapy for celiac | food-alt-protein | Medium | → |
Compiled by BIOECON via the bioecon-brief pipeline.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.